Stock Market Wrapup July 31st
Several data points came out today in the economic arena, chief among them consumer spending figures. The Commerce Department reported that consumer spending rose 0.1% in June, down from 0.5% in May. The dropoff in spending was due to still falling home prices as well as higher fuel costs. Incomes rose 0.4%. The Conference Board also said today that consumer confidence rose to a six-year high of 112.6. Meanwhile, the Association of Purchasing Management said that construction spending unexpectedly fell last month.
On the corporate earnings front, General Motors (NYSE: GM - News) said net income hit $891 million, or $1.56 a share, compared to a loss of -$3.48 billion, or -$5.98 a share. The automotive giant said revenues declined -13% to $46.8 billion. Excluding charges related to its restructuring, it would have earned $2.48 a share, which handily beat analyst estimates of $1.13 a share. Investors sent the shares up mid-day, but they fell with the overall market at the end of the day.
Elsewhere in earnings, tech giant Sun Microsystems (Nasdaq: SUNW - News) said it earned $329 million, or 9 cents a share, in its fiscal fourth quarter. It reported a loss of -$301 million, or -9 cents a share, in the same period a year ago. Revenues were little changed at $3.84 billion from $3.83 billion last year. Analysts were looking for a profit of 5 cents a share. Its management attributed its profit beat to cost cutting measures as its operating expenses fell by -25% in the quarter compared to last year. Shares rose 4.3% on the trading session.
Shares of the largest U.S. refiner Valero (NYSE: VLO - News) fell 3.0% after the company said it earned $2.25 billion, or $3.89 a share, up from $1.9 billion, or $2.98 a share, last year. Revenues fell -5.7% to $24.2 billion from $25.6 billion last year. Despite the falloff in revenue, higher refining margins and strong demand for petroleum products drove profits.
In other news, consumer products and pharmaceutical maker Johnson & Johnson (NYSE: JNJ - News) said that it would be eliminating -4% of its workforce, which will save the company $1.3-1.6 billion next year. The move comes amid two of its top-selling drugs facing generic competition. Shares rose 0.7%.
By the BullMarket.com Staff
